Today's story
Gilead and PAHO expand twice-yearly lenacapavir access to 14 nations outside licensing deals
On Sept. 16, 2026 Gilead and PAHO agreed to put twice-yearly lenacapavir HIV PrEP within reach of 14 nations outside voluntary licensing deals.
Health · 6 sources · Sep 16, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Gilead Sciences
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19. It also develops medicines in therapeutic areas such as oncology and inflammation and cell therapy.
Everything about Gilead Sciences →- Country
- United States
- Headquarters
- Foster City
- Inception
- June 1987
- Website
- https://www.gilead.com/